QPPV.COM

EU-RMP Structure Explained

A detailed guide to the structure of the EU Risk Management Plan and the purpose of each major section.

EU-RMP Structure Explained

Introduction

The Risk Management Plan (RMP) is one of the most important pharmacovigilance documents maintained throughout the lifecycle of a medicinal product. It describes what is known about a product's safety profile, which uncertainties remain, how additional information will be obtained and what measures are in place to minimise risks.

Many pharmacovigilance professionals understand individual RMP concepts such as Important Identified Risks or Additional Risk Minimisation Measures. However, fewer develop a clear understanding of how these concepts fit together within the overall structure of the document.

Understanding the architecture of the RMP is important because each section performs a specific function and contributes to the overall risk management strategy.

The Purpose of the EU-RMP

The EU-RMP is designed to answer four fundamental questions:

What are the important safety concerns?

What information is still missing?

How will additional safety information be obtained?

How will risks be minimised?

The structure of the RMP is organised around these questions.

Each major section contributes to one or more of these objectives.

High-Level Structure

Although templates evolve over time, modern EU-RMPs are generally organised around:

Part I
Product Overview

Part II
Safety Specification

Part III
Pharmacovigilance Plan

Part IV
Plans for Post-Authorisation Efficacy Studies

Part V
Risk Minimisation Measures

Part VI
Summary of the Risk Management Plan

The majority of pharmacovigilance activities focus on Parts II through V.

Part I: Product Overview

Part I provides administrative and product-specific information.

Typical content includes:

This section provides context for the remainder of the document.

Although not usually the focus of safety discussions, it establishes the scope of the RMP.

Part II: Safety Specification

Part II is the scientific core of the RMP.

It describes the current understanding of the product's safety profile.

The objective is to identify the safety concerns that require ongoing management.

Part II contains several subsections examining:

The most important output of this section is the Safety Concerns list.

Safety Concerns

Safety concerns are the foundation of the RMP.

Three categories are used:

Important Identified Risks

Risks for which sufficient evidence supports a causal association and which are considered important for product safety or benefit-risk evaluation.

Important Potential Risks

Risks for which evidence suggests a possible association but where uncertainty remains.

Missing Information

Important gaps in knowledge that may influence understanding of product safety.

Almost every subsequent section of the RMP is built around these safety concerns.

Why Safety Concerns Matter

Safety concerns determine:

A useful principle is:

No safety concern, no RMP activity.

Every major intervention within an RMP should be linked to a defined safety concern.

Part III: Pharmacovigilance Plan

Part III describes how additional safety information will be obtained.

The objective is to reduce uncertainty relating to safety concerns.

Activities may include:

This section explains how the MAH intends to further characterise identified risks, potential risks and missing information.

Routine Pharmacovigilance

Routine pharmacovigilance activities apply to virtually all medicinal products.

Examples include:

Routine activities generally do not require special justification.

They are expected components of a pharmacovigilance system.

Additional Pharmacovigilance Activities

Additional pharmacovigilance activities are implemented when routine activities are insufficient.

Examples include:

Additional activities should address specific uncertainties described within the safety specification.

Part IV: Post-Authorisation Efficacy Studies

Part IV describes any planned or ongoing efficacy studies relevant to benefit-risk evaluation.

This section is usually less prominent than the safety-focused sections of the RMP but may become important when efficacy uncertainties influence benefit-risk considerations.

Not all products require content within this section.

Part V: Risk Minimisation Measures

Part V describes how risks will be minimised.

This section is often the most visible component of the RMP because it translates safety concerns into practical interventions.

The section is divided into:

Routine Risk Minimisation Measures

Examples include:

Additional Risk Minimisation Measures

Examples include:

The objective is to reduce the likelihood or severity of adverse outcomes.

Effectiveness Evaluation

Modern RMPs increasingly focus on effectiveness evaluation.

Implementing a risk minimisation measure is not sufficient.

The MAH may also need to demonstrate that the measure achieves its intended objective.

Evaluation activities may include:

This section links risk minimisation activities to measurable outcomes.

Part VI: Summary of the Risk Management Plan

Part VI provides a public-facing summary.

The purpose is to communicate key aspects of the RMP in a format accessible to broader audiences.

The summary generally includes:

This section supports transparency and public communication.

How the Sections Connect

The most important concept for understanding RMPs is the relationship between sections.

The process can be visualised as:

Safety Concerns
        ↓
Pharmacovigilance Activities
        ↓
Risk Minimisation Measures
        ↓
Effectiveness Evaluation

Everything begins with the safety concerns.

If safety concerns change, the remainder of the RMP may need to change as well.

Relationship to Signal Management

Signal management is one of the principal drivers of RMP updates.

Signals may result in:

Consequently, signal management and risk management are closely interconnected.

Relationship to Benefit-Risk Evaluation

The RMP exists to support ongoing benefit-risk evaluation.

The significance of a safety concern depends upon:

RMP activities therefore contribute directly to understanding and maintaining a favourable benefit-risk balance.

Role of the QPPV

The QPPV should understand:

Inspectors frequently assess whether the QPPV maintains appropriate visibility of major risk management activities.

The expectation is oversight and understanding rather than document ownership.

Common Misunderstandings

Several misconceptions occur frequently.

The RMP is not simply a list of adverse reactions.

The RMP is not solely a regulatory submission document.

Additional activities should not exist without a linked safety concern.

Risk minimisation measures should not be implemented without a clear rationale.

Most importantly, the RMP should function as an integrated risk management strategy rather than a collection of independent sections.

Key Takeaways

The EU-RMP is structured around identification, characterisation and management of product risks.

Part II defines safety concerns.

Part III describes pharmacovigilance activities.

Part V describes risk minimisation measures.

All major RMP activities should be linked to defined safety concerns.

Understanding this structure provides the foundation for understanding all subsequent RMP concepts and lifecycle management activities.

References

  1. EMA Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems.
  2. EMA Risk Management Plan Template.
  3. Commission Implementing Regulation (EU) No 520/2012.
  4. Regulation (EC) No 726/2004.
  5. Directive 2001/83/EC.
  6. ICH E2E Pharmacovigilance Planning.
  7. EMA Guidance on Risk Management Systems.

Related Articles

Country-Specific RMP Annexes

A practical guide to managing country-specific RMP annexes, local commitments, version control and global risk management strategies.

Important Identified Risks

A practical guide to Important Identified Risks, including classification criteria, regulatory expectations and common RMP writing mistakes.

Missing Information

A practical guide to Missing Information, including classification criteria, regulatory expectations, lifecycle management and common RMP writing mistakes.

Last reviewed: 2026-06-11